Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 0.87 GBp
Change Today 0.00 / 0.00%
Volume 424.2K
As of 7:58 AM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

avacta group plc (AVCT) Snapshot

0.87 GBp
Previous Close
0.87 GBp
Day High
0.87 GBp
Day Low
0.87 GBp
52 Week High
04/23/14 - 1.21 GBp
52 Week Low
11/27/14 - 0.62 GBp
Market Cap
Average Volume 10 Days
-0.0004 GBp
Shares Outstanding
Dividend Yield
Current Stock Chart for AVACTA GROUP PLC (AVCT)

Related News

No related news articles were found.

avacta group plc (AVCT) Related Businessweek News

No Related Businessweek News Found

avacta group plc (AVCT) Details

Avacta Group plc researches, develops, produces, and delivers instrumentation and services for the biopharmaceutical drug development and clinical diagnostics markets using biophysical technology in the United Kingdom and internationally. It operates in three segments: Analytical, Animal Health, and Life Sciences. The Analytical segment provides tools and contract services for early stage protein characterization and analysis for biopharmaceutical drug developers. The Animal Health segment offers tools and contract services to assist diagnosis of conditions in animals to enable treatment for veterinarians. The Life Sciences segment provides reagents and arrays for diagnostics, drug, and biomarker discovery in biotech research and development. The company was incorporated in 2003 and is based in Wetherby, the United Kingdom.

Founded in 2003

avacta group plc (AVCT) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: 148.0K GBP
Chief Financial Officer, Company Secretary an...
Total Annual Compensation: 84.0K GBP
Compensation as of Fiscal Year 2013.

avacta group plc (AVCT) Key Developments

Avacta Group plc Enters into A Partnership with PhoreMost Limited

Avacta Group plc announced that it has entered into a commercial partnership with PhoreMost Limited to discover and commercialise new drug targets, Affimer reagents and therapeutics. The SiteSeeker technology requires a large library of binding proteins for which Affimers are ideal. SiteSeeker uses live cells, in what is called a phenotypic screen, to probe for unexpected and unexploited drug targets. PhoreMost aims to use Affimers in tandem with SiteSeeker to discover new drug targets and screen for small molecule therapeutics that act on these targets. In addition, this discovery programme will generate novel Affimers which could be used as reagents to assist in the drugs' development, or as therapeutics themselves. Under the terms of the agreement, Avacta is entitled to a royalty on PhoreMost's revenues that are generated using Affimers including near term services income from R&D partnerships, and on license income and future sales of all assets that are generated such as the new drug targets and small molecule therapeutics, as well as novel Affimers.

Avacta Group Plc Announces Development Contract with ProtATonce

Avacta Group plc announced that it has entered into a commercial partnership with ProtATonce to develop and commercialise high performance multiplexed assays for the Luminex platform using Affimers. ProtATonce is one of a number of exclusive Luminex partners selected to develop and commercialise multiplexed assays on the market leading Luminex xMAPTM platform which enables large numbers of biological tests to be conducted and analysed quickly using bead based assay kits. The bead based assay market is worth $270 million and around half of these assays are run using Luminex assay kits. ProtATonce specializes in developing high quality assays with high degrees of multiplexing to support the pharmaceutical industry in drug discovery, mode of action analysis and drug repositioning. The Luminex technology itself is powerful and capable of carrying out up to 500 tests in one experiment, but this high level of multiplexing is only possible if the antibodies that are used in the test kits are specific and show no cross reactivity between tests. However, the cross reactivity of antibodies practically limits the degree of multiplexing of the Luminex technology to around 50 tests. Under the terms of the agreement Avacta will provide Affimers to ProtATonce who will develop Affimer based assays that take advantage of the engineered specificity of Affimers to unlock the high multiplexing potential of the Luminex platform. The aim is for ProtATonce to develop assay kits with market leading, disruptive levels of multiplexing and commercialise these through larger commercial partners. Avacta will be entitled to a 50% share of future revenues derived from the Affimer based Luminex test kits with an agreed minimum annual sales level.

Gwyn Humphreys Resigns from the Board of Avacta Group plc

Avacta Group plc announced that Gwyn Humphreys stood down from the Board with immediate effect.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AVCT:LN 0.87 GBp 0.00

AVCT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AVCT.
View Industry Companies

Industry Analysis


Industry Average

Valuation AVCT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 8.2x
Price/Book 0.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 11.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AVACTA GROUP PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at